<SEC-DOCUMENT>0001144204-18-053318.txt : 20181011
<SEC-HEADER>0001144204-18-053318.hdr.sgml : 20181011
<ACCEPTANCE-DATETIME>20181011080044
ACCESSION NUMBER:		0001144204-18-053318
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20181011
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181011
DATE AS OF CHANGE:		20181011

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lipocine Inc.
		CENTRAL INDEX KEY:			0001535955
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				990370688
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36357
		FILM NUMBER:		181117288

	BUSINESS ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108
		BUSINESS PHONE:		801 994 7383

	MAIL ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARATHON BAR CORP
		DATE OF NAME CHANGE:	20111130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv504499_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of Earliest Event Reported):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>October 11, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIPOCINE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File No. 001-36357</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="width: 20%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: center"><FONT STYLE="font-size: 10pt">99-0370688</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>675 Arapeen Drive, Suite 202</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Salt Lake City, Utah 84108</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(801) 994-7383</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Former name or former address, if changed
since last report: <B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933&nbsp;(17 CFR &sect; 230.405) or&nbsp;Rule 12b-2 of the Securities
Exchange Act of 1934&nbsp;(17 CFR &sect; 240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to&nbsp;Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Item&nbsp;8.01</B> <B>Other Events</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 11, 2017, Lipocine Inc. issued a press release announcing
the late-breaker presentation of LPCN 1144 clinical data at The Liver Meeting&reg; 2018 in San Francisco, CA on November 12, 2018.
The press release is filed as Exhibit 99.1 and are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Additionally, the Company will
</FONT>highlight data from several clinical trials of its oral androgen therapy, LPCN 1144, in patients at-risk for non-alcoholic
fatty liver disease (&ldquo;NAFLD&rdquo;) / non-alcoholic steatohepatitis (&ldquo;NASH&rdquo;) at The Liver Meeting&reg; 2018.
<FONT STYLE="font-size: 10pt">The abstract is filed as Exhibit 99.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> Item 9.01 Financial Statements and Exhibits.</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are filed with this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 85.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit No.</U></FONT></TD>
    <TD STYLE="width: 82%; border-bottom: black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Description</U></FONT></P>
                                                           <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv504499_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD><A HREF="tv504499_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release Announcing the Late-Breaker Poster Presentation of LPCN 1144 Clinical Data at The Liver Meeting&reg; 2018</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv504499_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></A></TD>
    <TD><A HREF="tv504499_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abstract Entitled &ldquo;Oral Testosterone Undecanoate
Normalizes Liver Function Measures and Serum Triglycerides in Subjects At-Risk for Non-Alcoholic Fatty Liver Disease (&ldquo;NAFLD&rdquo;)&rdquo;</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">LIPOCINE INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">October 11, 2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Mahesh V. Patel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Mahesh V. Patel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv504499_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Lipocine Announces LPCN 1144 Clinical
Trial Results Selected for Late-Breaker Presentation at The Liver Meeting&reg; 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>SALT
LAKE CITY, UT, October 11, 2018 <I>&ndash;</I></B> <U>Lipocine Inc.</U> (NASDAQ: LPCN), a specialty pharmaceutical company, announced
today that it has been selected to present LPCN 1144 results as part of the late-breaker session of The Liver Meeting&reg; 2018.
The presentation will highlight data from multiple clinical trials of LPCN 1144 in potential non-alcoholic fatty liver disease
(&ldquo;NAFLD&rdquo;) / non-alcoholic</FONT> steatohepatitis <FONT STYLE="font-size: 10pt">(&ldquo;NASH&rdquo;) patients. The
Liver Meeting&reg; 2018, which is the annual meeting of the American Association for the Study of Liver Diseases (&ldquo;AASLD&rdquo;),
is being held November 9<SUP>th</SUP> &ndash; 13<SUP>th</SUP> in San Francisco, CA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I><U>Presentation Details</U></I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 3in">Title:</TD><TD>Oral Testosterone Undecanoate Normalizes Liver Function Measures and Serum Triglycerides in Subjects At-Risk for Non-Alcoholic
Fatty Liver Disease (&ldquo;NAFLD&rdquo;)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">Publication Number: &#9;LB-37</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; background-color: white">Date:&#9;&#9;Monday, November 12<SUP>th</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">Location:&#9;&#9;Moscone Center North/South Building, Hall C</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 3in">Time:</TD><TD>Monday, November 12: 8:00 am &ndash; 5:30 pm; Presenters Available: 12:30 pm&ndash;2:00 pm</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LPCN 1144 is an oral androgen targeting androgen signaling pathways.
The clinical studies to be presented include a randomized active-controlled clinical study designed to evaluate the efficacy, safety
and tolerability of oral androgen therapy in patients having testosterone deficiency and a randomized placebo-controlled clinical
study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&quot;We look forward to sharing the results from our clinical
trials with our well-tolerated, safe, oral androgen, LPCN 1144, as part of the late-breaker poster session at The Liver Meeting,&quot;
stated Mahesh Patel, Ph.D., Lipocine's Chairman, President and Chief Executive Officer. &quot;The observed reduction in serum liver
enzymes and lipids highlight the promise of LPCN 1144 as a potential therapy for NASH. Our proposed unique mechanism targets the
full spectrum of NASH pathogenesis with collateral health benefits associated with treating liver diseases.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Lipocine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Lipocine Inc.
is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its
proprietary drug delivery technologies. Lipocine's clinical development pipeline includes four development programs TLANDO, LPCN
1111, LPCN 1107 and LPCN 1144. &nbsp;TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed
to help restore normal testosterone levels in hypogonadal men. TLANDO&nbsp;received a Complete Response Letter from the FDA on
May 8, 2018.&nbsp; LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation
oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing.&nbsp; LPCN 1107 is potentially
the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been
granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. LPCN 1144, an oral androgen,
is being developed as a treatment of non-alcoholic steatohepatitis (&ldquo;NASH&rdquo;) and is currently being studied in two proof-of-concept
clinical studies. For more information, please visit&nbsp;www.lipocine.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This release contains
 &ldquo;forward looking statements&rdquo; that are made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 and include statements that are not historical facts regarding Lipocine&rsquo;s product candidates and related
clinical trials and the FDA review process relating to its product candidates, the path to approvability by the FDA of Lipocine&rsquo;s
development programs, the potential uses and benefits of our product candidates, including LPCN 1144, and our product development
efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation,
the risks that the FDA will not approve any of our products, risks related to our products, expected product benefits not being
realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks
related to the FDA approval process including the receipt of regulatory approvals, the results and timing of clinical trials, patient
acceptance of Lipocine&rsquo;s products, the manufacturing and commercialization of Lipocine&rsquo;s products, and other risks
detailed in Lipocine&rsquo;s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K
and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly
any forward-looking statements contained in this release, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>CONTACT: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Morgan Brown</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Executive Vice President &amp; Chief
Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Phone: (801) 994-7383</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>mb@lipocine.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Hans Vitzhum</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Phone: (646) 597-6979</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>hans@lifesciadvisors.com&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>tv504499_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Oral Testosterone Undecanoate Normalizes Liver Function Measures
and Serum Triglycerides in Subjects at Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Arun J. Sanya1<SUP>1</SUP>, Nachiappan Chidambaram<SUP>2
</SUP>, Satish Nachaegari<SUP>2</SUP> , Burke Byrne<SUP>2</SUP>, Kilyoung Kim<SUP>2</SUP>, Jonathan Baker<SUP>2</SUP> and Mahesh
V. Patel<SUP>2</SUP>, (1)Virginia Commonwealth University, Virginia, USA, (2)Lipocine Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Background</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A body of literature has associated male hypogonadism with
NAFLD, although it is unknown whether testosterone (T) therapy can treat this disease. In this report, we  compare the
effects of oral testosterone undecanoate (&ldquo;oral TU&rdquo;) on serum biomarkers of NAFLD in a randomized study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Methods</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This study (&ldquo;SOAR&rdquo; trial; NCT02081300) was an open
label, randomized, active-controlled study of oral TU versus topical T in men with hypogonadism. 210 men were randomized to the
oral TU arm and 105 men to the topical T arm. Data from post-hoc analysis of the oral TU arm is presented here.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Patients Comorbidity Distributions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">56% were obese (BMI&gt;30 Kg/m<SUP>2</SUP>), 48% hypertensive,
22% diabetic, and 9% metabolic syndrome (obesity, diabetes and hypertensive) in the oral TU arm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Cohort Analysis</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below shows the reductions of alanine transaminase
(ALT) and triglycerides (TG) post 52 week oral TU therapy as a function of cohort. In the table, N = number of subjects, BL = baseline
, CBL = change from baseline, and Q = quartile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="background-color: #D9D9D9">
    <TD ROWSPAN="2" STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Cohort</TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">N</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">ALT (U/L)</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">TG (mg/dL)</TD></TR>
<TR STYLE="background-color: #D9D9D9">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">BL</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">CBL</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">BL</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">CBL</TD></TR>
<TR>
    <TD STYLE="width: 20%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ALT &gt; 30 U/L</TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">81</TD>
    <TD STYLE="width: 18%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">44.5 (&plusmn;1.5)*</TD>
    <TD STYLE="width: 18%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-7.9 (&plusmn;1.6)</TD>
    <TD STYLE="width: 18%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">214 (&plusmn;28)</TD>
    <TD STYLE="width: 18%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-20 (&plusmn;12)</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ALT &gt; 40 U/L</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">42</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">53.6 (&plusmn;1.9)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-11.1 (&plusmn;2.9)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">227 (&plusmn;26)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-22 (&plusmn;16)</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">TG &gt; 200 mg/dL</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">73</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">34.4 (&plusmn;1.8)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-4.0 (&plusmn;1.5)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">320 (&plusmn;31)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-64 (&plusmn;15)</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">TG 4<SUP>th</SUP> Q</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">52</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">360 (&plusmn;26)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-85 (&plusmn;20)</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">ALT 4<SUP>th</SUP> Q</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">51</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">51.1 (&plusmn;1.7)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-10.0 (&plusmn;2.4)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Obese</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">118</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">33.3 (&plusmn;1.4)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-4.0 (&plusmn;1.2)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">205 (&plusmn;19)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-15 (&plusmn;8)</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Diabetes</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">46</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">29.4 (&plusmn;2.4)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-2.0 (&plusmn;1.7)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">209 (&plusmn;25)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-43 (&plusmn;18)</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Hypertensive</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">100</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">29.0 (&plusmn;1.4)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-2.9 (&plusmn;1.1)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">187 (&plusmn;16)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-26 (&plusmn;8)</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">Metabolic Syndrome</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">19</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">30.2 (&plusmn;3.3)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-4.5 (&plusmn;2.3)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">253 (&plusmn;40)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">-67 (&plusmn;25)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Lab values are mean (&plusmn;SE).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As shown in the table above, patients with metabolic syndrome
at BL had the greatest reductions in ALT and TG compared with other morbidities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Significant number of patients with above-normal levels of ALT
and TG at BL (N=42 for ALT and N=73 for TG) ended with normal levels post oral TU therapy (52% for ALT and 34% for TG).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The safety profile was consistent with that of the testosterone
replacement therapy class with no deaths, drug-related serious adverse events, major adverse cardiac events, serious or severe
hepatic disorders reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conclusion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This study relates to a population of individuals with
substantial risk factors for NAFLD. Administration of oral TU improves liver function measures in hypogonadal men with
elevated levels of serum liver enzymes and TG at baseline. Subjects with higher BL NAFLD biomarker levels had greater
improvements with oral TU at end-of-study. Hypogonadal men with metabolic syndrome had the greatest reductions of biomarkers
with oral TU therapy among all comorbidities. Similar findings were observed in another oral TU trial (NCT03242590). The
further study of oral TU in NAFLD is warranted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !8 0<# 2(  A$! Q$!_\0
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M7A'6I(W9'2PG964X((C;!!K@O@O?7=[::P;NZGG*O%M,LA;'#=,T >IT444
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M35K4/AUXSN=2NIX=>V122NZ+]JD& 22!B@#UZBO&/^%:>-_^AA_\FY?\*/\
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MWX=W_BOQ'<7&K:G?R#2T#A(M@ E<CH..@_G6%\'/^1OU/_K@W_H8H C^'?\
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$H __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
